OVARIAN ENDOMETRIOID ADENOCARCINOMA
Clinical trials for OVARIAN ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat ovarian cancer? early trial tests drug combo
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug called ipatasertib when given alongside standard chemotherapy drugs (paclitaxel and carboplatin) to patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding …
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Major trial tests new combo to fight back when ovarian cancer returns
Disease control OngoingThis large, late-stage trial is for people whose ovarian, fallopian tube, or primary peritoneal cancer has returned after initial successful treatment. It aims to find the best way to control the cancer by testing whether adding a drug called bevacizumab to standard chemotherapy,…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Major trial tests if weekly chemo beats standard schedule for tough cancers
Disease control OngoingThis large, Phase 3 trial aimed to find out if giving a key chemotherapy drug (paclitaxel) once a week is better than giving it once every three weeks for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. All patients also received another standard che…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Scientists test Two-Drug attack on tough brain and solid tumors
Disease control OngoingThis early-stage study is testing the safety and best dose of a new oral drug, MLN0128, when given with the existing cancer drug bevacizumab. It is for adults with recurrent glioblastoma (a type of brain tumor) or other advanced solid tumors that have stopped responding to standa…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for Tough-to-Treat ovarian cancer
Disease control OngoingThis study is testing whether a combination of two oral drugs, cediranib and olaparib, works better than either drug alone or standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemoth…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Scientists weaponize measles virus to fight ovarian cancer
Disease control OngoingThis study is testing a new treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after standard therapy. Doctors are using a specially engineered measles virus, which is carried directly to the cancer by the patient's own fat-derived stem cells, …
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for Tough-to-Treat ovarian cancers?
Disease control OngoingThis study is testing if adding an experimental drug called AZD1775 to a standard chemotherapy (gemcitabine) works better than the chemotherapy alone. It is for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to platinum-based…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
New targeted attack on tough ovarian cancer tested against standard care
Disease control OngoingThis study is for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. It compares a new two-drug combination (bevacizumab + anetumab ravtansine) against a standard two-drug combination (bevacizumab + paclit…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
Two-Pronged attack on tough cancers shows promise
Disease control OngoingThis study tested a combination of two drugs, cediranib and olaparib, for people with recurrent ovarian, fallopian tube, peritoneal, or triple-negative breast cancer. The goal was to see if using both drugs together is safe and works better than using olaparib alone to control th…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC